Hepato-cellular cancer, the most common liver cancer, accounts for more than 90% of fatalities in America due to its ability to spread quickly undetected.

The company’s novel molecule miRNA 101 for therapy against liver cancer has been allowed for issuance of a USA patent after the prosecution on merits have been closed, it added.
HCC is the most common primary liver cancer, accounting to roughly 90% of this class of malignancy, with poor prognosis due to its ability to rapidly spread, Transgene Biotek said.
The company’s current product portfolio covers segments such as oncology, auto-immunity, drug delivery and bio-generics.
Shares of Transgene Biotek closed 4.90% up at Rs 2.57 per scrip on the BSE.
Source-Medindia